B.V.S. Suneel Kumar, D. Sriram and P. Yogeeswari Pages 1939 - 1939 ( 1 )
The role of the medicinal chemistry in drug discovery industry has undergone major changes in the past two decades, due to the development of new technologies such as combinatorial chemistry, computational biology and chemisty [1-3]. Over the years, tremendous research has carried out towards the designing new chemical entities for various therapeutic areas using recent technologies such as combinatorial chemistry and virtual screening approaches. In current issue of “Current Topics in Medicinal Chemistry (CTMC)”, we focused on the literature review on potential therapeutic targets, and virtual screening strategies towards the design and discovery of new chemical entities in entitled the special topic with “Medicinal chemistry update and discovery strategies on potential therapeutic targets”. Articles in this special issue have been contributed by experts from many parts of the world. In first article, Drs. Rahul and Se Won Park covered extensive step-by-step summary of anti-HIV breakthroughs of triterpene acid analogues and their derivatives with synthetic and activity aspects, featuring fertile clues for novel anti-HIV drug design, which helps to develop unprecedented opportunities to discover the next-generation anti-HIV armamentarium. In second article, Drs. Riyaz and Ahmed Kamal has covered a brief review on tankyrase inhibitors and its structure activity relationships (SAR). In the next article, Drs. Siddharth Malik & Suneel has covered list of small molecule inhibitors targeting anthrax lethal factor activity and its structure-activity relationships (SAR). In the another article, Drs. Shalini & Sriram has discussed about most of potent series of DNA gyrase inhibitors & its structure activity relationships (SAR). The current manuscript also reports the current research on identification of potent DNA gyrase inhibitors using ligand based virtual screening approaches. In next article, Drs. Raghu & Vijaya Lakshmi has covered an overview to the available crystal complexes of Aurora Kinases and their co-crystal interactions and also quantified with glide-extra precision (XP) docking. Also covers identification of potential leads against aurora kinase using various rational methods of drug discovery. In the next article, Drs. Singh & Sarma has describes an overview on clinical candidates of PARP1 and its current status in clinical trials and also discussed about recent study on identification of potent PARP1 inhibitors using structure and ligand based pharmacophore models. In the last article, Drs. Suneel & Sarma has discussed about recent study on identification of potent FGFR1 inhibitors using ligand based virtual screening approach.Editorial, (Thematic, Issue:, Medicinal, Chemistry, Updates, and, Discovery, Strategies, on, Potential, Therapeutic, Targets)
SAI Life Sciences Ltd, Building No. 1, Plot No. 2 Chrysalis Enclave International Biotech Park, Phase – II Hinjewadi, Pune – 411057 India.